Drug intelligence / Profile preview

TRV045

Development stage: Unknown
Lead developer: Trevena
Modality: Small Molecules
Administration: Oral

Overview

TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain, particularly diabetic peripheral neuropathy, and epilepsy. It demonstrates sustained analgesic effects without causing receptor desensitization or lymphopenia, unlike other S1P modulators like fingolimod. TRV045 is developed by Trevena, Inc.

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on TRV045.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRV045.

Explore the full profile